Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice

MeSH terms

• Antineoplastic Agents, Hormonal / therapeutic use*
• Aromatase Inhibitors / therapeutic use*
• Breast Neoplasms / drug therapy*
• Breast Neoplasms / mortality
• Chemotherapy, Adjuvant
• Clinical Trials as Topic
• Disease-Free Survival
• Endpoint Determination
• Female
• Humans
• Patient Selection
• Survival Analysis
• Tamoxifen / therapeutic use*
• Treatment Outcome